Cogent Biosciences, Inc.

o In June, secured a debt financing facility of up to $400 million with SLR Capital Partners.

SEC original ↗Cogent Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

T he company expects its existing cash, cash equivalents and marketable securities, together with the net proceeds from the $230 million upsized public offering in July 2025, will be sufficient to fund its operating expenses and capital expenditure requirements into 2027, including through potential FDA approval of bezuclastinib for NonAdvSM and early commercial launch activities.

SEC original ↗Cogent Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

As of the issuance date of the interim condensed consolidated financial statements, the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from issuance of the condensed consolidated financial statements.

SEC original ↗Cogent Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

The Company will need to seek additional funding through equity offerings, debt financings, collaborations, licensing arrangements or other marketing and distribution arrangements, partnerships, joint ventures, combinations or divestitures of one or more of its assets or businesses.

SEC original ↗Cogent Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Marketable Securities The Company s marketable securities, consisting of debt securities, are classified as available-for-sale.

SEC original ↗Cogent Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Available-for-sale marketable debt securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders equity until realized.

SEC original ↗Cogent Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported financial results for the second quarter ended June 30, 2025.

SEC original ↗Cogent Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases.

SEC original ↗Cogent Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions.

SEC original ↗Cogent Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, anticipated regulatory approval and commercial launch of bezuclastinib, business strategy and plans, and objectives of management for future operations, are forward-looking statements.

SEC original ↗Cogent Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

( Cogent or the Company ) is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases.

SEC original ↗Cogent Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.

SEC original ↗Cogent Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption Risk Factors in Cogent's most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC.

SEC original ↗Cogent Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

SEC original ↗Cogent Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in Item 1A Risk Factors.

SEC original ↗Cogent Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events.

SEC original ↗Cogent Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Legal Proceedings 30 Item 1A.

SEC original ↗Cogent Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026